By Professor David Goldstein

Journal articles

McGrane JA; Butow PN; Sze M; Eisenbruch M; Goldstein D; King MT, 2014, 'Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis', Quality of Life Research, 23, pp. 2819 - 2830, http://dx.doi.org/10.1007/s11136-014-0717-5

Jefford M; Nolte L; Tsintziras S; Butow P; Sze M; Yiu D; Schofield P; Goldstein D; Price M, 2014, 'HOW IS POST-TREATMENT SURVIVORSHIP CONCEPTUALISED BY PEOPLE FROM DIFFERENT CULTURAL GROUPS?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 10, pp. 158 - 158, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000346343700480&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wang X; Goldstein D; Crowe PJ; Yang JL, 2014, 'Impact of STAT3 inhibition on survival of osteosarcoma cell lines', Anticancer Research, 34, pp. 6537 - 6545

McGrane J; Butow P; Sze M; Eisenbruch M; Goldstein D; King M, 2014, 'Assessing the Invariance of a Culturally Competent Multi-lingual Unmet Needs Survey for Immigrant and Australian-born Cancer Patients: A Rasch Analysis', PSYCHO-ONCOLOGY, 23, pp. 153 - 153, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344003700220&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hillman RJ; Garland SM; Gunathilake MPW; Stevens M; Kumaradevan N; Lemech C; Ward RL; Meagher A; McHugh L; Jin F; Carroll S; Goldstein D; Grulich AE; Tabrizi SN, 2014, 'Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers', International Journal of Cancer, 135, pp. 996 - 1001, http://dx.doi.org/10.1002/ijc.28730

Vernerey D; Hammel P; Paget-Bailly S; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Moore M; André T; Mineur L; Chibaudel B; Louvet C; Bonnetain F, 2014, 'Prognosis Model for Overall Survival in Locally Advanced Pancreatic Cancer (LAPC): An Ancillary Study of the Lap 07 Trial', Annals of Oncology, 25, pp. ii105, http://dx.doi.org/10.1093/annonc/mdu193.2

McGrane JA; Butow PN; Sze M; Eisenbruch M; Goldstein D; King MT, 2014, 'Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis', Quality of Life Research, http://dx.doi.org/10.1007/s11136-014-0717-5

Sears K; Broderick B; Goldstein D; Stockley D, 2014, 'The Development of a New Master’s of Science in Healthcare Quality Program', Collected Essays on Learning and Teaching, 7, pp. 39 - 45, http://dx.doi.org/10.22329/celt.v7i1.3991

Goldstein D; EI-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Macarulla T; Teixeira L; Tortora G; Van Laethem JL; Penenberg DN; Lu B; Romano A; Von Hoff DD, 2014, 'Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).', JOURNAL OF CLINICAL ONCOLOGY, 32, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.4027

Tempero MA; Cardin DB; Biankin A; Goldstein D; Moore M; O'Reilly EM; Philip PA; Riess H; Macarulla T; Yung L; Wei X; Lu B, 2014, 'APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).', Journal of Clinical Oncology, 32, pp. TPS4162 - TPS4162, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps4162

Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im S-A; Gupta S; Kang Y-K; Schoffski P; Schuette J; Soulieres D; Blay J-Y; Goldstein D; Fly KD; Huang X; Corsaro M; Lechuga M; Martini J-F; Heinrich MC, 2014, 'Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.', JOURNAL OF CLINICAL ONCOLOGY, 32, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.10549

Huguet F; Hammel P; Vernerey D; Goldstein D; Van Laethem JL; Glimelius B; Spry N; Paget-Bailly S; Bonnetain F; Louvet C, 2014, 'Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.', Journal of Clinical Oncology, 32, pp. 4001 - 4001, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.4001

Vernerey D; Hammel P; Paget-Bailly S; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Moore M; André T; Mineur L; Chibaudel B; Louvet C; Bonnetain F, 2014, 'Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.', Journal of Clinical Oncology, 32, pp. 4024 - 4024, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.4024

Davis ID; Long A; Martin A; Espinoza D; Yip S; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Stockler MR, 2014, 'EVERSUN: A PHASE 2 TRIAL OF EVEROLIMUS ALTERNATING WITH SUNITINIB AS FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA (ANZUP TRIAL 0901)', EUROPEAN JOURNAL OF CANCER, 50, pp. E68 - E69, http://dx.doi.org/10.1016/j.ejca.2014.03.255

Valle JW; Palmer D; Jackson R; Cox T; Neoptolemos JP; Ghaneh P; Rawcliffe CL; Bassi C; Stocken DD; Cunningham D; O'Reilly D; Goldstein D; Robinson BA; Karapetis C; Scarfe A; Lacaine F; Sand J; Izbicki JR; Mayerle J; Dervenis C; Oláh A; Butturini G; Lind PA; Middleton MR; Anthoney A; Sumpter K; Carter R; Büchler MW, 2014, 'Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study', Journal of Clinical Oncology, 32, pp. 504 - 512, http://dx.doi.org/10.1200/JCO.2013.50.7657

Ramanathan RK; Von Hoff DD; Moore MJ; Teixeira L; Siena S; Tabernero J; Goldstein D; Wei X; Lu B, 2014, 'Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas', JOURNAL OF CLINICAL ONCOLOGY, 32, http://dx.doi.org/10.1200/jco.2014.32.3_suppl.254

Goldstein D; El Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem J-L; Young R; Wei X; Lu B; Romano A; Von Hoff DD, 2014, 'Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas', JOURNAL OF CLINICAL ONCOLOGY, 32, http://dx.doi.org/10.1200/jco.2014.32.3_suppl.178

Bennett BK; Goldstein D; Chen M; Davenport TA; Vollmer-Conna U; Scott EM; Hickie IB; Lloyd AR, 2014, 'Characterization of fatigue states in medicine and psychiatry by structured interview', Psychosomatic Medicine, 76, pp. 379 - 388, http://dx.doi.org/10.1097/PSY.0000000000000061

Goldstein D; Bell ML; Butow P; Sze M; Vaccaro L; Dong S; Liauw W; Hui R; Tattersall M; Ng W; Asghari R; Steer C; Vardy J; Parente P; Harris M; Karanth NV; King M; Girgis A; Eisenbruch M; Jefford M, 2014, 'Immigrants' perceptions of the quality of their cancer care: An Australian comparative study, identifying potentially modifiable factors', Annals of Oncology, 25, pp. 1643 - 1649, http://dx.doi.org/10.1093/annonc/mdu182

Greenhalf W; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Lamb RF; Garner E; Campbell F; MacKey JR; Costello E; Moore MJ; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Halloran CM; Mayerle J; Oláh A; Jackson R; Rawcliffe CL; Scarpa A; Bassi C; Büchler MW, 2014, 'Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial', Journal of the National Cancer Institute, 106, http://dx.doi.org/10.1093/jnci/djt347

McCarroll JA; Naim S; Sharbeen G; Russia N; Lee J; Kavallaris M; Goldstein D; Phillips PA, 2014, 'Role of pancreatic stellate cells in chemoresistance in pancreatic cancer', Frontiers in Physiology, 5 APR, pp. 141, http://dx.doi.org/10.3389/fphys.2014.00141

Von Hoff DD; Goldstein D; Renschler MF, 2014, 'The authors reply', New England Journal of Medicine, 370, pp. 479 - 480, http://dx.doi.org/10.1056/NEJMc1314761

Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS, 2014, 'The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: Anti-angiogenic implications in pancreatic cancer', Carcinogenesis, 35, http://dx.doi.org/10.1093/carcin/bgu122

Murray JE; Pickering HR; Lin CS-Y; Goldstein D; Friedlander ML; Kiernan MC; Krishnan AV, 2014, '6. Functional impact of neuropathy in patients receiving oxaliplatin chemotherapy', Clinical Neurophysiology, 125, pp. e3 - e3, http://dx.doi.org/10.1016/j.clinph.2013.10.028

Tempero M; Cardin D; Biankin A; Goldstein D; Moore M; O’Reilly E; Philip P; Riess H; Macarulla T; Yung L; Wei X; Lu B, 2014, 'APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)', American Journal of Gastroenterology, 109, pp. S72 - S72, http://dx.doi.org/10.14309/00000434-201410002-00232

Tempero MA; Cardin D; Biankin A; Goldstein D; Moore M; O'Reilly EM; Philip PA; Riess H; Macarulla T; Yung L; Wei X; Lu B, 2014, 'Apact: a Phase III Trial of Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Resected Pancreatic Cancer (Pc)', Annals of Oncology, 25, pp. iv252 - iv252, http://dx.doi.org/10.1093/annonc/mdu334.131

Huguet F; Hammel P; Vernerey D; Van Laethem J; Goldstein D; Glimelius B; Bonnetain F; Louvet C, 2014, 'Impact de la chimioradiothérapie sur le contrôle local et le temps sans traitement dans l’essai de phase III LAP07', Cancer/Radiothérapie, 18, pp. 587 - 587, http://dx.doi.org/10.1016/j.canrad.2014.07.013

Hammel P; Huguet F; Dewi V; Laethem J-LV; Goldstein D; Glimelius B; Artru P; Borbath Y; Bonnetain F; Louvet C, 2014, 'Impact of chemoradiotherapy (CRT) on local tumour control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study', Pancreatology, 14, pp. S6 - S6, http://dx.doi.org/10.1016/j.pan.2014.05.398

McCarroll J; Teo J; Boyer C; Goldstein D; Kavallaris M; Phillips PA, 2014, 'Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer', Frontiers in Physiology, 5, pp. 1 - 10, http://dx.doi.org/10.3389/fphys.2014.00002

Siena S; Lipton L; Letourneau R; Tjulandin SA; Guillen Ponce C; Schwarz M; Ramanathan RK; Macarulla T; Goldstein D; Romano A; Ferrara S; Penenberg D; Von Hoff DD, 2014, 'Regional Subanalysis of the Phase III Mpact Trial: Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients (Pts) with Metastatic Pancreatic Cancer (Pc)', Annals of Oncology, 25, pp. iv235 - iv235, http://dx.doi.org/10.1093/annonc/mdu334.76

Bell ML; Butow PN; Goldstein D, 2013, 'Informatively missing quality of life and unmet needs sex data for immigrant and Anglo-Australian cancer patients and survivors', Quality of Life Research, 22, pp. 2757 - 2760, http://dx.doi.org/10.1007/s11136-013-0392-y

Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, http://dx.doi.org/10.1002/caac.21204

Kashigar A; Habbous S; Eng L; Irish B; Bissada E; Irish J; Brown D; Gilbert R; Gullane P; Xu W; Huang SH; Witterick I; Freeman J; O'Sullivan B; Waldron J; Liu G; Goldstein D, 2013, 'Erratum: Social environment, secondary smoking exposure, and smoking cessation among head and neck cancer patients. (Cancer (2013) 119 (27019))', Cancer, 119, pp. 3895 - 3896, http://dx.doi.org/10.1002/cncr.28281

Ackland S; Goldstein D; McJannett M, 2013, 'Forty years of COSA - Contributions to oncology teaching and research', Cancer Forum, 37, pp. 238 - 242

Tan K; Goldstein D; Crowe P; Yang JL, 2013, 'Uncovering a key to the process of metastasis in human cancers: A review of critical regulators of anoikis', Journal of Cancer Research and Clinical Oncology, 139, pp. 1795 - 1805, http://dx.doi.org/10.1007/s00432-013-1482-5

Huguet F; Racadot S; Goldstein D; Spry N; Van Laethem J; Van Houtte P; Glimelius B; Gubanski M; Bonnetain F; Hammel P, 2013, 'Investigation of Relation of Radiation Therapy Quality Assurance Scores (RTQASc) With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma (LAPC)', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87, pp. S29 - S30, http://dx.doi.org/10.1016/j.ijrobp.2013.06.080

Kiely BE; Martin AJ; Tattersall MHN; Nowak AK; Goldstein D; Wilcken NRC; Wyld DK; Abdi EA; Glasgow A; Beale PJ; Jefford M; Glare PA; Stockler MR, 2013, 'The median informs the message: Accuracy of individualized scenarios for survival time based on oncologists' estimates', Journal of Clinical Oncology, 31, pp. 3565 - 3571, http://dx.doi.org/10.1200/JCO.2012.44.7821

Grimison P; Phillips F; Butow P; White K; Yip D; Sardelic F; Underhill C; Tse R; Simes R; Turley K; Raymond C; Goldstein D, 2013, 'Are visiting oncologists enough? A qualitative study of the needs of Australian rural and regional cancer patients, carers and health professionals', Asia-Pacific Journal of Clinical Oncology, 9, pp. 226 - 238, http://dx.doi.org/10.1111/ajco.12014

Chou A; Waddell N; Cowley MJ; Gill AJ; Chang DK; Patch AM; Nones K; Wu J; Pinese M; Johns AL; Miller DK; Kassahn KS; Nagrial AM; Wasan H; Goldstein D; Toon CW; Chin V; Chantrill L; Humphris J; Mead RS; Rooman I; Samra JS; Pajic M; Musgrove EA; Pearson JV; Morey AL; Grimmond SM; Biankin AV, 2013, 'Clinical and molecular characterization of HER2 amplified-pancreatic cancer', Genome Medicine, 5, pp. 78, http://dx.doi.org/10.1186/gm482

Shaw J; Butow P; Sze M; Young J; Goldstein D, 2013, 'Reducing disparity in outcomes for immigrants with cancer: A qualitative assessment of the feasibility and acceptability of a culturally targeted telephone-based supportive care intervention', Supportive Care in Cancer, 21, pp. 2297 - 2301, http://dx.doi.org/10.1007/s00520-013-1786-7

Butow PN; Sze M; Eisenbruch M; Bell ML; Aldridge LJ; Abdo S; Tanious M; Dong S; Iedema R; Vardy J; Hui R; Boyle F; Liauw W; Goldstein D, 2013, 'Should culture affect practice? A comparison of prognostic discussions in consultations with immigrant versus native-born cancer patients', Patient Education and Counseling, 92, pp. 246 - 252, http://dx.doi.org/10.1016/j.pec.2013.03.006

Huguet F; Van Laethem J-L; Goldstein D; Glimelius B; Artru P; Borbath I; Bouche O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C, 2013, 'Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.', J Clin Oncol, 31, pp. LBA4003, http://dx.doi.org/10.1200/jco.2013.31.18_suppl.lba4003

Teo J; Erlich RB; Sagnella S; Dwarte T; Davis TP; Kavallaris M; McCarroll J; Boyer C; Duong HTT; Phillips P; Sharbeen G; Goldstein D, 2013, 'Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers', Molecular Pharmaceutics, 10, pp. 2435 - 2444, http://dx.doi.org/10.1021/mp400049e

Chiorean EG; Von Hoff DD; Ervin TJ; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; Ko A; Lu B, 2013, 'CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).', Journal of Clinical Oncology, 31, pp. 4058 - 4058, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4058

Hammel P; Huguet F; Van Laethem J-L; Goldstein D; Glimelius B; Artru P; Borbath I; Bouche O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C, 2013, 'Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.', Journal of Clinical Oncology, 31, pp. LBA4003 - LBA4003, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.lba4003

Pavlakis N; Goldstein D; Sjoquist KM; Martin A; Tsobanis E; Yip S; Shannon J; Burge ME; Cronk MF; Tebbutt NC; Strickland A; Lipton LR; Price TJ; Nott LM; Harris DL; Burnell MJ; Alcindor T; Bang Y-J; Kang Y-K; O'Callaghan CJ, 2013, 'INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG).', Journal of Clinical Oncology, 31, pp. TPS4157 - TPS4157, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps4157

Moore MJ; Von Hoff DD; Ervin TJ; Arena FP; Chiorean EG; Infante JR; Hon JK; Biakhov MY; Hingorani SR; Ganju V; Weekes CD; Scheithauer W; Ramanathan RK; Tabernero J; Goldstein D; Wei X; Romano A, 2013, 'Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).', Journal of Clinical Oncology, 31, pp. 4059 - 4059, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4059

Von Hoff DD; Ervin TJ; Arena FP; Chiorean EG; Infante JR; Moore MJ; Seay TE; Tjulandin S; Ma WW; Saleh MN; Harris M; Reni M; Ramanathan RK; Tabernero J; Hidalgo M; Van Cutsem E; Goldstein D; Wei X; Iglesias JL; Renschler MF, 2013, 'Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.', Journal of Clinical Oncology, 31, pp. 4005 - 4005, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4005

Butow PN; Sze M; Eisenbruch M; Bell M; Aldridge L; Vardy JL; Hui R; Boyle F; Liauw WS; Goldstein D, 2013, 'Should culture affect practice? Prognostic discussions with immigrants.', Journal of Clinical Oncology, 31, pp. 6556 - 6556, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.6556

Vickers MM; Tu D; Lee C; Wheatley-Price P; Parulekar W; Brundage MD; Moore MJ; Au H-J; O'Callaghan CJ; Jonker DJ; Ringash J; Goldstein D, 2013, 'Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.', Journal of Clinical Oncology, 31, pp. 4053 - 4053, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4053

Back to profile page